Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $2.8 billion.

  • United Therapeutics' Cash & Current Investments fell 1680.14% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 1680.14%. This contributed to the annual value of $3.3 billion for FY2024, which is 911.46% up from last year.
  • As of Q3 2025, United Therapeutics' Cash & Current Investments stood at $2.8 billion, which was down 1680.14% from $3.0 billion recorded in Q2 2025.
  • United Therapeutics' Cash & Current Investments' 5-year high stood at $3.3 billion during Q3 2024, with a 5-year trough of $1.7 billion in Q1 2021.
  • In the last 5 years, United Therapeutics' Cash & Current Investments had a median value of $2.8 billion in 2025 and averaged $2.7 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 4702.96% in 2022, then plummeted by 1680.14% in 2025.
  • United Therapeutics' Cash & Current Investments (Quarter) stood at $1.9 billion in 2021, then soared by 47.03% to $2.8 billion in 2022, then rose by 5.47% to $3.0 billion in 2023, then grew by 9.11% to $3.3 billion in 2024, then decreased by 15.29% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q3 2025, $3.0 billion for Q2 2025, and $3.3 billion during Q1 2025.